



# Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?

Pantelis Sarafidis<sup>1</sup> and George Bakris<sup>2</sup>

*Diabetes Care* 2020;43:1684–1686 | <https://doi.org/10.2337/dci20-0019>

Hypertension and diabetes are prominent cardiovascular (CV) risk factors and major issues of public health (1,2). The common coexistence of hypertension and type 2 diabetes is long-established and represents a “deadly” combination: diabetes increases CV risk threefold at any level of systolic blood pressure (SBP), while the presence of hypertension in patients with diabetes increases CV risk by fourfold (3,4).

The optimal level of blood pressure (BP) in patients with diabetes has been a matter of debate for many years (5–7). Following older observational evidence and interventional data from the UK Prospective Diabetes Study (UKPDS) 38 and Hypertension Optimal Treatment (HOT) study, which showed CV benefits with diastolic blood pressure (DBP) of <85 mmHg and <80 mmHg, hypertension and diabetes guidelines from the late 1990s suggested a BP target of <130/80 mmHg in diabetes (8,9). However, until the Action to Control Cardiovascular Risk in Diabetes blood pressure trial (ACCORD BP) (10) was performed, the bulk of the data regarding the SBP target were derived from observational studies. ACCORD BP aimed to identify the optimal SBP goal by randomizing 4,733 high-risk patients (i.e., >15% 10-year CV risk) with type 2 diabetes to a target SBP of <120 mmHg or <140 mmHg. After 4.7 years

of follow-up, the two groups had no differences in the primary outcome (nonfatal myocardial infarction, nonfatal stroke, death from CV causes) (hazard ratio [HR] 0.88, 95% CI 0.73–1.06;  $P = 0.20$ ), CV mortality, and all-cause mortality; those in the intensive group had fewer stroke events (HR 0.59, 95% CI 0.39–0.89) but a higher incidence of serious adverse events (3.3% vs. 1.3%,  $P < 0.001$ ), including hypotension, syncope, arrhythmias, hyperkalemia, angioedema, and renal failure.

The ACCORD BP findings were considered by many as conclusive evidence against the <130 mmHg SBP target and favoring the <140 mmHg target in diabetes and led to changes in relevant recommendations (11,12). However, this interpretation met criticism for several reasons (6,7). ACCORD was a 2 × 2 factorial design trial, where the initially well-powered group for target BP assessment lost power following the premature termination of the ACCORD glycemia study (due to high mortality in the intensive glycemia group) (13). The intensive SBP target of <120 mmHg and the method of measurement, which were similar to those in the Systolic Blood Pressure Intervention Trial (SPRINT), did not follow clinical practice or existing guidelines recommending a target of <130 mmHg (14). Moreover, from 1 year to the study end, the mean SBPs were 119.3 and

133.5 mmHg, respectively, i.e., the low actual BPs achieved in the “conservative” target may have diluted any between-group differences in outcome. A higher event rate could have favored the “intensive” target group, as relative risks of most outcomes in ACCORD BP pointed toward benefit with the “intensive” target. Hence, no firm answer was achieved by ACCORD BP.

A previous post hoc analysis explored the combined effects of BP and glycemia regimes in ACCORD by allocating patients into four groups and yielded results contrasting the main ACCORD BP analysis (15). Patients in the intensive BP/intensive glycemia (HR 0.71, 95% CI 0.52–0.96), intensive BP/standard glycemia (HR 0.74, 95% CI 0.55–1.00), and standard BP/intensive glycemia groups (HR 0.67, 95% CI 0.50–0.91) all had reduced risk of the primary outcome when compared with the standard BP/standard glycemia group. All secondary outcomes were neutral or favored the intensive treatment groups. Another post hoc analysis of ACCORD BP (16) investigated the effect of intensive SBP control in patients with >9 years of follow-up. They included participants in the standard glycemia arm who had established CV disease, had chronic kidney disease (CKD), were aged ≥75 years, or had a 10-year coronary heart risk ≥15%. Intensive SBP control reduced

<sup>1</sup>Department of Nephrology, Hippokraton Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

<sup>2</sup>American Heart Association Comprehensive Hypertension Center, Department of Medicine, The University of Chicago Medicine, Chicago, IL

Corresponding author: Pantelis Sarafidis, [psarafidis11@yahoo.gr](mailto:psarafidis11@yahoo.gr)

© 2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/content/license>.

See accompanying article, p. 1878.

the composite outcome by 25% (HR 0.75, 95% CI 0.60–0.95), with the benefit driven mostly by a reduction in nonfatal myocardial infarction.

Since the original analyses by Franklin (17) showing that SBP largely determines CV outcomes in people over age 50 years, there has been less attention paid to DBP. There continues to be a controversy, however, regarding the J-curve phenomenon, i.e., the concern whether intensive SBP lowering could result in increased CV events due to an extreme decrease in DBP (18). This question is particularly relevant in individuals with increased arterial stiffness and high pulse pressure (i.e., the elderly, those with CKD or diabetes). In this issue of *Diabetes Care*, Ilkun et al. (19) present a post hoc analysis of 4,731 ACCORD BP patients, examining whether baseline DBP modifies the effects of intensive SBP control on outcomes. The analysis was performed separately for patients in the standard and intensive glycemia arms, and the study population was categorized into three groups by baseline DBP ( $\leq 70$ , 71–79, or  $\geq 80$  mmHg). Those with DBP  $\leq 70$  mmHg were older and had a higher prevalence of heart failure, CKD, history of stroke or myocardial infarction, and a longer duration of diabetes. Within each tertile of baseline DBP, the mean achieved DBP during follow-up was lower for the intensive SBP group (i.e., for baseline DBP  $\leq 70$ , achieved mean DBPs were  $60 \pm 6$  vs.  $65 \pm 6$  mmHg for intensive and standard SBP groups, respectively).

In the standard glycemic arm, intensive SBP lowering decreased the risk of the ACCORD BP primary composite outcome (HR 0.76, 95% CI 0.59–0.98). As indicated by spline regression analysis, this effect of low SBP was not related to baseline DBP (linear interaction term for baseline DBP as a continuous variable  $P = 0.67$ ). With DBP considered a dichotomous variable, the risk for the primary outcome with intensive SBP lowering was similar for those with DBP  $\leq 70$  mmHg (HR 0.76, 95% CI 0.50–1.17) and DBP  $> 70$  mmHg (HR 0.78, 95% CI 0.56–1.07), interaction  $P = 0.96$ . Conversely, in the intensive glycemic arm, intensive SBP lowering did not reduce the composite outcome risk (HR 1.06, 95% CI 0.81–1.40); again, this outcome was not affected by baseline DBP as a linear (interaction  $P = 0.85$ ) or dichotomous

(interaction  $P = 0.92$ ) variable. Moreover, intensive SBP lowering did not affect all-cause mortality in any glycemic arm. No interactions with baseline DBP were noted in the standard glycemic arm. However, in the intensive glycemia arm, intensive SBP lowering signified a risk for participants with DBP  $\leq 70$  mmHg (HR 1.93, 95% CI 1.18–3.14), interaction  $P = 0.04$  (19).

The strengths of this study include the large original sample and a thorough statistical analysis employing Cox regression, cubic spline models, and a large set of sensitivity analyses. Examining the impact of baseline DBP both as a continuous and a dichotomous variable adds to the validity of the conclusions. However, the study is limited by its post hoc nature and the low power for included subgroup analyses, resulting in progressively wider confidence intervals.

These data are of interest when placed in the context of other analyses. Unlike the current study that chose a cut point of  $< 70$  mmHg for DBP, much of the concern relates to DBP levels  $< 60$  mmHg where coronary autoregulatory flow reserve may be compromised in advanced atherosclerosis and contribute to acute flow obstruction. Data from an Atherosclerosis Risk in Communities (ARIC) study cohort of 11,565 adults (31% with prediabetes or diabetes) evaluated associations between DBP and outcomes over 6 years (20). DBP  $< 60$  mmHg at baseline was independently associated with progressive myocardial damage based on the annual change in hs-cTnT. Additionally, compared with a DBP of 80–89 mmHg, a DBP  $< 60$  mmHg was associated with incident coronary heart disease and mortality but not with stroke. A separate post hoc analysis of the SPRINT trial, including participants without diabetes, demonstrated a U-shaped association between baseline DBP and the risk of the primary CV outcome (21). However, the effects of intensive SBP intervention on the primary outcome were not influenced by baseline DBP ( $P$  for interaction = 0.83). The primary outcome HR in the intensive versus standard SBP group was 0.78 (95% CI 0.57–1.07) in the lowest DBP quintile (mean baseline DBP  $61 \pm 5$  mmHg) with an interaction  $P$  value of 0.78. Results were similar for all-cause death and renal events. The authors concluded that low baseline DBP was associated with increased risk of CV disease events, but the benefit of the intensive SBP lowering did not differ by baseline DBP.

Ilkun et al. (19) suggest that in patients with diabetes and standard glycemic control, there was no effect of baseline DBP on the ability of low SBP to reduce CV risk. While this may be true, it appears from older data that those at highest risk of having DBP  $< 60$  mmHg are those with higher magnitudes of atherosclerosis (22). Thus, the existence of a J- or U-shaped curve between the achieved levels of DBP and CV events, while highly debated, may depend more on the pre-existing state of atherosclerosis and a magnitude of DBP drop below 60 mmHg (18,22). A relevant open discussion regards the possibility that the J- or U-curve is not a result of purely low DBP but rather of increased pulse pressure reflecting high arterial stiffness and, therefore, increased CV risk (23). Given the fact that the vast majority of existing literature on the J-curve phenomenon derives also from observational studies or post hoc analyses of outcome trials, the current study, taken together with data from SPRINT in individuals without diabetes, provides important evidence against the interference of low baseline DBP (at levels  $< 70$  mmHg and not  $< 60$  mmHg) on the CV benefits of low SBP. These promising observations call for confirmation in future trials.

**Duality of Interest.** P.S. is an advisor/speaker to Amgen, Bayer, Boehringer Ingelheim, Elpen Pharmaceuticals, Genesis Pharma, Menarini, Innovis Pharma, and Winmedica and has received research support for an Investigator-Initiated Study from AstraZeneca. G.B. serves on the 2020–2021 American Diabetes Association Clinical Practice Guideline committee and is a consultant for Merck, Novo Nordisk, Bayer, Janssen, AstraZeneca, Relypsa, and Vascular Dynamics.

## References

- de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. *Diabetes Care* 2017;40:1273–1284
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension* 2018;71:e13–e115
- American Diabetes Association. 10. Cardiovascular disease and risk management: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care* 2020;43(Suppl. 1):S111–S134

4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993;16:434–444
5. Sarafidis PA, Bakris GL. Use of a single target blood pressure level in type 2 diabetes mellitus for all cardiovascular risk reduction: comment on “intensive and standard blood pressure targets in patients with type 2 diabetes mellitus.” *Arch Intern Med* 2012;172:1304–1305
6. Sarafidis PA, Lazaridis AA, Ruiz-Hurtado G, Ruilope LM. Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. *Nat Rev Endocrinol* 2017;13:365–374
7. Papadopoulou E, Angeloudi E, Karras S, Sarafidis P. The optimal blood pressure target in diabetes mellitus: a quest coming to an end? *J Hum Hypertens* 2018;32:641–650
8. de Boer IH, Bakris G, Cannon CP. Individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC/AHA recommendations. *JAMA* 2018;319:1319–1320
9. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. *Am J Kidney Dis* 2014;64:510–533
10. ACCORD Study Group; Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1575–1585
11. American Diabetes Association. Standards of medical care in diabetes—2013. *Diabetes Care* 2013;36(Suppl. 1):S11–S66
12. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014;311:507–520
13. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545–2559
14. Bakris G, Ali W, Parati G. ACC/AHA versus ESC/ESH on hypertension guidelines: JACC guideline comparison. *J Am Coll Cardiol* 2019;73:3018–3026
15. Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. *Diabetes Care* 2014;37:1721–1728
16. Buckley LF, Dixon DL, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassell BW. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: a subgroup analysis of high-risk ACCORDION trial participants. *Diabetes Obes Metab* 2018;20:1499–1502
17. Franklin SS. Cardiovascular risks related to increased diastolic, systolic and pulse pressure. An epidemiologist’s point of view. *Pathol Biol (Paris)* 1999;47:594–603
18. Okamoto R, Kumagai E, Kai H, et al. Effects of lowering diastolic blood pressure to <80 mmHg on cardiovascular mortality and events in patients with coronary artery disease: a systematic review and meta-analysis. *Hypertens Res* 2019;42:650–659
19. Ilkun OL, Greene T, Cheung AK, et al. The influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering on cardiovascular outcomes and all-cause mortality in type 2 diabetes. *Diabetes Care* 2020;43:1878–1884
20. McEvoy JW, Chen Y, Rawlings A, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. *J Am Coll Cardiol* 2016;68:1713–1722
21. Beddhu S, Chertow GM, Cheung AK, et al.; SPRINT Research Group. Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. *Circulation* 2018;137:134–143
22. Bangalore S, Messerli FH, Wun CC, et al.; Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. *Eur Heart J* 2010;31:2897–2908
23. Kannel WB, Wilson PW, Nam BH, D’Agostino RB, Li J. A likely explanation for the J-curve of blood pressure cardiovascular risk. *Am J Cardiol* 2004;94:380–384